"/>

日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

FDA approves new drug for patients with multi-drug-resistant HIV

Source: Xinhua    2018-03-07 06:07:40

WASHINGTON, March 6 (Xinhua) -- The United States Food and Drug Administration (FDA) approved on Tuesday a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.

Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

"Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options. New treatment options may be able to improve their outcomes," said Jeff Murray, deputy director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research.

While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death, according to FDA.

The safety and efficacy of Trogarzo were evaluated in a clinical trial of 40 heavily treatment-experienced patients with multi-drug resistant HIV-1 who continued to have high levels of virus (HIV-RNA) in their blood despite being on antiretroviral drugs. Many of the participants had previously been treated with 10 or more antiretroviral drugs.

The majority of participants experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their failing antiretroviral regimens.

After 24 weeks of Trogarzo plus other antiretroviral drugs, 43 percent of the trial's participants achieved HIV RNA suppression, FDA said.

A total of 292 patients with HIV-1 infection have been exposed to Trogarzo IV infusion. The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea and rash. Severe side effects included rash and changes in the immune system.

Editor: Liu
Related News
Xinhuanet

FDA approves new drug for patients with multi-drug-resistant HIV

Source: Xinhua 2018-03-07 06:07:40

WASHINGTON, March 6 (Xinhua) -- The United States Food and Drug Administration (FDA) approved on Tuesday a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past and whose HIV infections cannot be successfully treated with other currently available therapies.

Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

"Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options. New treatment options may be able to improve their outcomes," said Jeff Murray, deputy director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research.

While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death, according to FDA.

The safety and efficacy of Trogarzo were evaluated in a clinical trial of 40 heavily treatment-experienced patients with multi-drug resistant HIV-1 who continued to have high levels of virus (HIV-RNA) in their blood despite being on antiretroviral drugs. Many of the participants had previously been treated with 10 or more antiretroviral drugs.

The majority of participants experienced a significant decrease in their HIV-RNA levels one week after Trogarzo was added to their failing antiretroviral regimens.

After 24 weeks of Trogarzo plus other antiretroviral drugs, 43 percent of the trial's participants achieved HIV RNA suppression, FDA said.

A total of 292 patients with HIV-1 infection have been exposed to Trogarzo IV infusion. The most common adverse reactions to Trogarzo were diarrhea, dizziness, nausea and rash. Severe side effects included rash and changes in the immune system.

[Editor: huaxia]
010020070750000000000000011100851370207631
主站蜘蛛池模板: 波多野结衣在线观看一区二区 | 日穴视频在线观看 | 国产中文字幕在线免费观看 | 国产一级片免费 | 亚洲精品无码不卡在线播放 | 国产片在线观看.com | 无码精品AV久久久奶水小说 | 亚洲国产精品视频观看 | 又大又粗又硬又爽黄毛少妇 | 亚洲欧美综合一区二区 | 丝袜国偷自产中文字幕亚洲第一页 | 人妻系列无码中文字幕专区 | 亚洲欧美日韩精品久久亚洲区色播 | 全免一级毛片 | 欧美18—19sex性护士中国 | 超碰在线成人 | 欧美综合社区 | 久久久女人 | 水蜜桃视频免费在线观看 | 国产一区二区精品久久99 | 高潮绝顶抽搐大叫久久精品 | 日日久视频 | 日本精品在线免费观看 | 韩日av一区二区三区 | 成年女美黄网站大全免费播放 | 成人国产精品高清在线观看 | 在线综合亚洲 | 国产一国产一级毛片视频 | 欧洲性受xxxx黑人xyx性爽 | 国产999在线 | 国产综合视频一区二区三区 | av资源站最稳定的资源站 | 真实的国产乱ⅩXXX66V | 国产亚洲综合专区在线在线观看 | 久久人人妻人人爽人人卡片av | 黄瓜tv在线观看 | 曰本无码人妻丰满熟妇5g影院 | 特级无码A级毛片特黄 | 一二三四区在线视频 | 少妇中文字幕乱码亚洲影视 | 国产无遮挡裸体免费视频A片 |